What we do

For almost 50 years we’ve been creating high-quality medicines and making them accessible to the people who need them.

Learn more about how we do this across North America, MENA and Europe.

Investors

Together we are building a leading generics and specialty pharmaceutical company where everyone can thrive.

Learn more about our strategy, investment case and track record of success.

Responsibility

Learn more about how we put better health within reach, every day and make a difference to people’s lives.

Careers

We're looking for people who share our passion and want to help us make a real difference in the world.

Newsroom

Featured

Press Release, Financial Results 07 August 2025

Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 29 September 2025 Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half Press Release, Financial Results 07 August 2025 Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Hikma remains a constituent of the FTSE4Good Index Press Release, Corporate 16 July 2025 Hikma remains a constituent of the FTSE4Good Index
Hikma launches Morphine Sulfate Injection, USP, in a prefilled syringe in the US Press Release, Product 14 July 2025 Hikma launches Morphine Sulfate Injection, USP, in a prefilled syringe in the US